Founded in 2021 and based in New York, Helex leverages genomics data, bioinformatics, and an intelligent data-driven platform to create, verify, and distribute therapy-specific gRNAs. The company's core mission is to develop breakthrough gene editing-based therapeutics to address significant unmet medical needs, particularly focusing on genetic kidney diseases such as Autosomal Dominant Polycystic Kidney Disease (ADPKD). Helex aims to revolutionize genomic medicines and provide first-in-class treatments for chronic kidney disease patients worldwide.
Notable affiliated individuals and investors have yet to be publicly disclosed. However, Helex has made significant strides in the field of gene editing-based therapeutics. The company's innovative approach and specialized focus on kidney diseases have positioned it as a promising player in the biotech industry. By addressing large unmet medical needs, Helex is poised to make a substantial impact on the lives of millions suffering from chronic kidney diseases globally.
